Literature DB >> 22042216

Understanding and treating comorbid anxiety disorders in substance users: review and future directions.

Kate Wolitzky-Taylor1, Joachim T Operskalski, Richard Ries, Michelle G Craske, Peter Roy-Byrne.   

Abstract

Anxiety disorders commonly occur among those with substance use disorders. This article reviews the literature describing the prevalence and patterns of this comorbidity in epidemiological and clinical samples and theoretical models explaining this comorbidity, and reviews the effects of anxiety disorders on substance use outcomes and data from clinical trials that target comorbid anxiety disorders to examine the effects of treating anxiety disorders on substance use outcomes. Next, this review outlines evidence-based pharmacological and psychological treatments for anxiety disorders and provides treatment recommendations for those treating this comorbid population. Finally, a discussion of treatment-delivery issues is presented to address the important issues that arise when treating anxiety disorders in typical addictions-treatment settings.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22042216     DOI： 10.1097/ADM.0b013e31823276d7

Source DB:  PubMed          Journal:  J Addict Med        ISSN： 1932-0620            Impact factor:   3.702


  11 in total

1.  Randomized clinical trial evaluating the preliminary effectiveness of an integrated anxiety disorder treatment in substance use disorder specialty clinics.

Authors:  Kate Wolitzky-Taylor; Jennifer Krull; Richard Rawson; Peter Roy-Byrne; Richard Ries; Michelle G Craske
Journal:  J Consult Clin Psychol       Date:  2018-01

Review 2.  At the crossroads: the intersection of substance use disorders, anxiety disorders, and posttraumatic stress disorder.

Authors:  Lesia M Ruglass; Teresa Lopez-Castro; Soumia Cheref; Santiago Papini; Denise A Hien
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

3.  Metacognition in Pathological Gambling and Its Relationship with Anxious and Depressive Symptomatology.

Authors:  Paula Jauregui; Irache Urbiola; Ana Estevez
Journal:  J Gambl Stud       Date:  2016-06

4.  Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry.

Authors:  Karen G Chartier; Katherine Sanchez; Therese K Killeen; Allison Burrow; Thomas Carmody; Tracy L Greer; Madhukar H Trivedi
Journal:  Am J Addict       Date:  2015-02-17

Review 5.  Exploring the comorbidity of anxiety and substance use disorders.

Authors:  Sonja Pasche
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

6.  The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care.

Authors:  Kate Wolitzky-Taylor; Lily A Brown; Peter Roy-Byrne; Cathy Sherbourne; Murray B Stein; Greer Sullivan; Alexander Bystritsky; Michelle G Craske
Journal:  J Anxiety Disord       Date:  2015-01-08

Review 7.  Exercise training - A beneficial intervention in the treatment of alcohol use disorders?

Authors:  Mark Stoutenberg; Chad D Rethorst; Olivia Lawson; Jennifer P Read
Journal:  Drug Alcohol Depend       Date:  2015-11-22       Impact factor: 4.492

8.  Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.

Authors:  Michael P Bogenschutz; Snehal Bhatt; Juliane Bohan; Bellelizabeth Foster; Paul Romo; Claire E Wilcox; J Scott Tonigan
Journal:  Am J Drug Alcohol Abuse       Date:  2016-05-16       Impact factor: 3.829

9.  Correlation of Alcohol Use Disorders with Common Mental Disorders and Its Association with Socio-demographic Characteristics Among Community in Ethiopia: A Cross-sectional Study.

Authors:  Zakir Abdu; Mohammedamin Hajure
Journal:  Risk Manag Healthc Policy       Date:  2020-12-08

10.  Developing and validation of identifying people in risk of addiction questionnaire (I.p.R.a).

Authors:  Jafar Anisi; Mohammad Hossein Bahadori; Marziyeh Jahanbakhsh
Journal:  Int J High Risk Behav Addict       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.